logo
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe and Mail13 hours ago
Quanterix Corporation ('Quanterix' or the 'Company') (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units ('RSUs') representing 267,269 shares of Quanterix common stock to twenty employees newly-hired in connection with the acquisition of Akoya Biosciences, Inc. The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company. The RSUs vest in full on the one year anniversary of the grant date, subject to the applicable individual's continued employment with the Company or one of its subsidiaries through the vesting date.
About Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

‘It could have sat on your shoulder': Scientists discover North America's oldest pterosaur
‘It could have sat on your shoulder': Scientists discover North America's oldest pterosaur

CTV News

timean hour ago

  • CTV News

‘It could have sat on your shoulder': Scientists discover North America's oldest pterosaur

An artist's reconstruction of the fossilized landscape, plants and animals found preserved in a remote bonebed in Petrified Forest National Park in Arizona. (Illustration by Brian Engh) A team led by the Smithsonian has discovered North America's oldest known pterosaur—a small, seagull-sized flying reptile that lived more than 200 million years ago in what is now Arizona. According to the report published in Proceedings of the National Academy of Sciences, the fossil was found in a remote part of Petrified Forest National Park. It includes part of the animal's jaw and a wing bone, dating back to nearly 209 million years ago, making it the earliest known pterosaur from the continent. 'There are two other Triassic pterosaur fossils from the North American continent, one from Greenland and one from Utah, but they're both younger than the one we found,' Ben Kligman, the study's lead author and a postdoctoral fellow at the Smithsonian's National Museum of Natural History, said in a video interview with The new species is named Eotephradactylus mcintireae, meaning 'ash-winged dawn goddess,' referring to the volcanic ash that helped preserve it in an ancient riverbed. 'The animal itself would have been the size of a small seagull, so it could have sat on your shoulder,' Kligman said adding that it likely fed on armoured fish in the river system it once flew over. pterosaur Kay Behrensmeyer, curator of vertebrate paleontology at the Smithsonian's National Museum of Natural History, in Petrified Forest National Park documenting the geology of a bonebed in 2023. 'The teeth in the jaw of this pterosaur … all are worn down,' he explained. 'It means that this pterosaur was eating something with a hard skeleton or hard bony parts, and the fish that were living in this river system … would be covered by an armoured skin.' The find sheds light on a time just before a mass extinction wiped out three-quarters of the world's species and set the stage for dinosaurs to dominate. The fossil was uncovered with more than 1,200 other specimens, including bones from ancient amphibians, one of the world's oldest turtles and a crocodile relative. Most early pterosaur fossils have been found in Europe and are flattened by pressure from layers of ocean sediment, but the Arizona discovery was preserved in three dimensions, allowing scientists to study fine details like tooth placement and replacement teeth growing inside the jaw. pterosaur Ben Kligman, a Peter Buck Postdoctoral Fellow and paleontologist at the Smithsonian's National Museum of Natural History, quarrying a bonebed in Arizona's Petrified Forest National Park in 2025. '(They are) animals that could fly, so their bones are oftentimes hollow, and they are difficult to collect,' Kligman said. 'If you have a tiny two-centimetres-long little hollow bone, it's really easy for it to break apart … and it's hard to even recognize the fossil.' Kligman says similar fossils are likely across the world because pterosaurs could fly, so they didn't have barriers to their dispersal. He hopes the modern scanning techniques that his team used can open the door for more discoveries in similar riverbed deposits. 'We're hoping through showing a methodology for finding, collecting, preparing and then CT scanning these bones, (we can) open a pathway for us and other researchers to reexamine these Triassic river deposits and hopefully find more pterosaurs.'

10 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
10 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

Globe and Mail

timean hour ago

  • Globe and Mail

10 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

Key Points Technology remains at the heart of most growth opportunities. Artificial intelligence and the data centers needed to house these platforms are also key growth drivers. A handful of stocks from the healthcare arena are also capitalizing on contemporary technological developments. 10 stocks we like better than Amazon › Are you looking for passive growth investments with staying power that you won't need to constantly monitor? That's a combination that doesn't often co-exist for any individual stock. There are some exceptions, however. Here's a rundown of 10 such growth stocks that would be at home in nearly any growth-minded investor's portfolio. Still worthy after all these years It's such a commonly suggested pick that it's almost become a cliché. Nevertheless, e-commerce and cloud computing giant Amazon (NASDAQ: AMZN) remains one of the market's most promising long-term growth prospects. Yes, plenty of other companies like Walmart and Shopify are finally figuring out how to keep Amazon in check. These other players aren't exactly dethroning Amazon, though. Market research outfit Digital Commerce 360 reports Amazon's leading share of North America's e-commerce market is holding strong at around 40%, while Synergy Research Group says Amazon Web Services' share of global cloud computing is a market-leading 29%. Amazon may not be adding market share on either front, but being the biggest name in both businesses helps it maintain its share of each. As long as the e-commerce and cloud computing markets keep growing -- and they're each expected to -- Amazon remains a serious growth engine. Plugged into the semiconductor industry's ongoing growth While Amazon is a household name, Lam Research (NASDAQ: LRCX) is anything but. Don't let its lack of notoriety fool you, though. It's an important player within the ever-growing semiconductor market. No, Lam doesn't make microchips. It makes the equipment used to manufacture microchips. Thin-film layering, plasma etching, wafer-cleaning, plus the software needed to operate these technologies are all in its wheelhouse, and more. Chipmakers Intel, Samsung, and Taiwan Semiconductor Manufacturing are some of its customers, for perspective. Yes, other companies also make semiconductor manufacturing tools. Making microchips is a complicated process with many different specialized steps, though. Few other players in the business are able to offer the specific solutions that Lam Research can, however, just as no other name in the business can provide ASML 's ultraviolet lithography technology, or offer Axcelis Technologies ' ion implanters. We need all these tools, including Lam's. And that need isn't going away anytime soon. It's only going to grow, in fact. An outlook from Precedence Research suggests the worldwide semiconductor market is set to double in size between now and 2034. Growth in a social and economic silo is still growth Amazon may be the powerhouse e-commerce name where you live, but that's not the case everywhere. In its home country of China, Alibaba (NYSE: BABA) is king, with collective control of about 40% of that online shopping market (according to numbers from wealth management firm DBS Treasures). It's doing pretty well with several of China's neighboring countries, too. All told, Alibaba's Tmall and Taobao e-commerce platforms did nearly $20 billion worth of business last year, up 29% year over year. And yet, this company's got far more ways to make money. It operates a logistics and delivery arm, a digital entertainment business, and perhaps most important, a cloud computing division that's also waist-deep into artificial intelligence. Remember the Qwen platform that posed a credible threat to ChatGPT, Google's Gemini, and then-buzzy DeepSeek earlier this year? Well, Qwen is Alibaba's developmental AI. As long as the Pacific Rim chooses to build its economy and technological landscape in a manner that's somewhat walled off from the Western world's, Alibaba stock is a growth investment that's parallel to -- rather than overlapping with -- Amazon. The growing norm in operating rooms Given how technology has become the centerpiece of most aspects of our lives, it should come as no surprise that it's also now frequently found within the healthcare industry. It's even found within operating rooms, in the tools used by surgeons. And one company dominates this sliver of the market: Intuitive Surgical (NASDAQ: ISRG). It makes the da Vinci surgical robot that's becoming the go-to solution for performing a growing number of surgical procedures ranging from hysterectomies to mitral vale repair to gastric sleeves to colostomies, just to name a few. Intuitive Surgical reports its da Vinci robots helped perform nearly 2.7 million procedures last year, up 17% from 2023's count. Here's the thing -- this still only scratches the surface of the tool's potential. Intuitive Surgical regularly adds capabilities to the da Vinci's toolkit at the same time more and more surgeons become qualified to use it, making them more likely to use this tech on one of the 300 million surgical procedures performed worldwide every year. Simultaneously, Intuitive Surgical is still developing new solutions like the Ion for lung biopsies and Hub, which records and shares surgical procedures. Analysts are calling for 25% top-line growth from Intuitive Surgical this year, to be followed by 15% and 17% revenue growth in 2026 and 2027, respectively. This is likely only a taste of what's to come further down the road, as this tech continues to prove itself. You've actually never heard of most software You're certainly familiar with Microsoft 's Windows operating system, and you may well be a regular user of its office productivity tools like Word and Excel. What you may not realize, however, is that most software is so industry-specific that you've likely never even heard of it. Case in point: Cadence Design Systems ' (NASDAQ: CDNS) Fidelity CFD (computational fluid dynamics) that digitally tests the behavior of fluids under certain conditions, or its Allegro X Design Platform, used to make printed circuit boards. Most people would never need such a specialized solution. But the few who need these tools desperately need them to do their job, and will pay a premium to gain access to them. This marketability is only part of the argument for buying and holding this stock for the long haul, however. Even more compelling is the fact that 80% of Cadence's revenue is now recurring revenue, meaning its customers are making ongoing, regular payments to access this software. It's much easier -- and cheaper -- to retain a customer than win one in the first place. A new kind of networking solution Cisco Systems may be the biggest name in the networking business, but it's not necessarily the best investment opportunity within the industry. That honor arguably belongs to smaller Arista Networks (NYSE: ANET). At first blush, the two companies seem similar enough. As was noted, both are networking solutions providers, offering a range of switches and buffers. There is a nuanced but important difference between these two outfits, though. That is, most of Arista's tech is built around its Extensible Operating System that can be updated and/or rewritten as merited. Because its switches are always equipped to meet ever-changing functionality needs, they will remain useful for longer. This ultimately translates into lower lifetime equipment costs for campuses, telecommunications service providers, and the like. Analysts are looking for sales growth of more than 19% this year and next, although this pace of growth is apt to last far longer in light of the solution that Arista brings to the table. Think small for big growth and big profits Most investors have heard of Vertex Pharmaceuticals (NASDAQ: VRTX). Most people, however, would be hard-pressed to name a single drug it makes. But that's kind of the point. It's predominantly a specialty pharma company, focusing on relatively rare diseases and underserved markets. Vertex is really, really good at what it does. Last year's revenue of just over $11 billion was up 12% from 2023's sales, and the company is looking for sales of nearly $12 billion this year following two key approvals. If all goes as expected, 2025 is going to mark the pharma company's 11th straight year of double-digit revenue growth. Given its pipeline that includes two phase 3 clinical trials in addition to four phase 2 trials, however, it's certainly possible that firmly profitable Vertex can keep the streak alive for far longer than that. If it works, it works You've probably never heard of Coupang (NYSE: CPNG). But don't sweat it. It's relatively new as well as relatively small. And, although headquartered in the United States, it mostly serves the South Korean market. The company did $30 billion worth of business last year, up 24%. But what is it? Like so many other technology companies these days, it's a little bit of everything. Its core business is e-commerce and delivery of online orders, but its distinguishing detail is its exposure to the grocery and restaurant-prepared food delivery market. Yet it's also a major middleman for entertainment events -- digital as well as in-person -- an online payment platform, and a seller of luxury goods. The thing is, this disjointed assembly of ventures seems to work, perhaps because the company's management fully understands its core geographic market and its consumers. Electric vehicle mania is still alive and well ... in China U.S. consumers may have lost their lovin' feelin' for electric vehicles, just as the U.S. electric vehicle industry lost much of its political support (in the form of subsidies). But this isn't the case outside of the United States. The rest of the world still loves the idea of emissions-free electric vehicles, including most foreign governments. And it's particularly true in China, where EV maker Nio (NYSE: NIO) is located, and where it does the bulk of its growing business. It delivered nearly 222,000 electric cars in 2024, up 39% from the previous year's count. This growth pace has persisted into the first half of this year as well, boosted by sustained demand for electric vehicles in China and its neighbors. Indeed, the International Energy Administration says electric vehicles accounted for nearly half of China's automobile sales in 2024. There's plenty more where that came from, too. The IEA adds that by 2030, this proportion should reach 80% of the country's total vehicle sales. The data center industry can't grow without it Finally, add Applied Digital (NASDAQ: APLD) to your list of brilliant growth stocks to buy and hold for the long haul. It's an opportunity hiding in plain sight. The rapid growth of artificial intelligence data centers? Most investors are so focused on the technology being used inside them that they're not even thinking about who's building the buildings themselves. It's Applied Digital, for one, which is arguably the best and most (if not only) investment-worthy one. It's easier said than done. As you likely know, AI data centers are incredibly power-hungry, so much so that onsite nuclear power is being considered as a cost-effective source of the electricity they need. Applied Digital isn't just stacking up processors. It's figuring out how to provide the power that data centers need at the lowest cost possible. This might put things in perspective. Although this year's forecasted top-line growth of more than 34% is likely to cool to nearly nil next year, this company's revenue is expected to more than double in 2027, and then triple this year's sales in 2028. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,432!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,005,854!* Now, it's worth noting Stock Advisor 's total average return is1,049% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 7, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends ASML, Amazon, Arista Networks, Cadence Design Systems, Cisco Systems, Intel, Intuitive Surgical, Lam Research, Microsoft, Shopify, Taiwan Semiconductor Manufacturing, Vertex Pharmaceuticals, and Walmart. The Motley Fool recommends Alibaba Group and Coupang and recommends the following options: long January 2026 $395 calls on Microsoft, short August 2025 $24 calls on Intel, and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

This Stock Outperformed Nvidia and Palantir in the First Half. Is It Still a Buy?
This Stock Outperformed Nvidia and Palantir in the First Half. Is It Still a Buy?

Globe and Mail

timean hour ago

  • Globe and Mail

This Stock Outperformed Nvidia and Palantir in the First Half. Is It Still a Buy?

Key Points CoreWeave stock surged by 300% in just a few months. The company is benefiting from high demand for computing power to support AI training and inferencing. 10 stocks we like better than CoreWeave › Over the past couple of years, Nvidia (NASDAQ: NVDA) and Palantir Technologies (NASDAQ: PLTR) have both shown their strengths in artificial intelligence (AI) -- and as a result, their earnings and stock performance have soared. Last year, Nvidia was the best-performing component in the Dow Jones Industrial Average (though it only was added to the venerable blue chip index in November), and Palantir posted the biggest gain in the S&P 500. Both of these players have continued to advance, and considering that we're in the early stages of the AI boom, more earnings growth and stock price gains could be on the way. But, in the first half of 2025, another company emerged as a potential AI powerhouse. In fact, this particular stock actually outperformed Nvidia and Palantir in the period, climbing by a mind-boggling 300%. Now you may be wondering whether this high flyer is still a buy. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » A company with close ties to Nvidia This top-performing AI stock actually is new to the market, completing its initial public offering in late March, so its triple-digit gains took place over a period of only three months. I'm referring to CoreWeave (NASDAQ: CRWV), a company that is closely linked to Nvidia. This is because CoreWeave generates most of its revenue by renting out access to its vast collection of Nvidia graphics processing units (GPUs). The company has more than 250,000 of them deployed across its cloud infrastructure platform, and it specializes in handling AI workloads, offering customers the configurations they need to accomplish their goals faster. CRWV data by YCharts. Nvidia owns a 7% stake in CoreWeave, and made it possible for the young company to be the first to launch its latest GPUs. In February, CoreWeave became the first hyperscaler to make Nvidia's new Blackwell architecture broadly available -- and it just did the same recently with the latest iteration, Blackwell Ultra. So, a bet on CoreWeave is a bet on demand for Nvidia's latest chips. Its first-quarter earnings report showed this demand is going strong, as its revenue climbed by more than 400% year over year, and Nvidia's own Q1 earnings report offered additional clues: For example, Nvidia said it saw a leap in demand for inferencing computing power in the quarter. This sort of trend is likely to benefit CoreWeave. GPUs to fuel inferencing Inferencing is the process an AI model goes through when attempting to answer complex questions -- and it takes significant parallel processing power of the type provided by GPUs and other AI accelerators. As more people and organizations apply AI to real-world problems, inferencing could drive a whole new era of growth for companies like Nvidia and CoreWeave. It's important to remember that the need for GPUs doesn't end once a model is trained. CoreWeave's fleet of cloud servers may have plenty of busy days ahead over the long term. All of this is great, but CoreWeave still carries some risk for shareholders -- and that's due to the enormous and ongoing investments in infrastructure required to serve demand for GPUs. The company will have to keep up its capital spending to increase the size and power of its fleet of GPU clusters, and considering that Nvidia aims to roll out new chip architectures annually, CoreWeave will have to make those investments frequently to keep its offerings top of the line. All of this makes it difficult to estimate when CoreWeave will reach profitability. In the first quarter, its technology and infrastructure expenses surged by more than 500% to about $500 million, and it's fair to say the company is early in its growth story. It's also important to note that CoreWeave is in an expansion phase that involves other investments too. Some of those up-front costs may result in savings down the road. Acquiring Core Scientific One example is the company's recently announced plan to buy Core Scientific -- once that deal closes, CoreWeave no longer will have to pay rent to the data center operator, resulting in the savings of $10 billion in future lease payments. Though this will be a positive, CoreWeave's stock fell after the announcement earlier this week due to investors' concerns about share dilution -- it's an all-stock deal with a value of $9 billion. Investors also know that any acquisition comes with some risks and costs, as the buyer will have to integrate its new operations into its existing business. So the question remains: After strongly outperforming two of the market's biggest AI companies year to date, is CoreWeave still a buy? The answer depends on your investment strategy. If you're a cautious or value investor, you'd be better off exploring other opportunities. But if you're an aggressive investor who buys and holds stocks for the long term, now would still be a good time to add a few CoreWeave shares to your portfolio -- demand for AI and CoreWeave's immediate access to Nvidia's latest GPUs could result in major gains over the long run. Should you invest $1,000 in CoreWeave right now? Before you buy stock in CoreWeave, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CoreWeave wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,432!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,005,854!* Now, it's worth noting Stock Advisor 's total average return is1,049% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 7, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store